{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:51:26Z","timestamp":1784692286259,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale &amp; objective<\/jats:title>\n                    <jats:p>Thrombotic Microangiopathies (TMAs) include an etiological diverse group of phenotypically similar disorders. While individually rare, they are seen as an aggregate with regularity. Prior reports suggested the importance of approaching TMAs in a multidisciplinary fashion. We present the development and data over a 4-year period after establishing the University of California Irvine (UCI) TMA team.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, settings, participants, and measurements<\/jats:title>\n                    <jats:p>This is a single-center retrospective case observational study of 101 diverse patients demonstrating demographics, diagnoses, triggers, treatments applied, and outcomes representing a wide range of hematologic pathologies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Of the 101 patients, 47 were females with an age range between 18 and 83 years old. 46 of our 101 patients were diagnosed with TMA. 24 patients were diagnosed with atypical hemolytic uremic syndrome (aHUS). Eight patients were diagnosed with Hematopoietic Stem Cell Transplant TMA (HSCT-TMA). Of the 24 aHUS patients, 16 were treated and 8 were evaluated for complement blockade. Of those treated, 100% demonstrated a hematologic response, 81.3% had initial renal remission and 68.8% of those who were on dialysis (11 of 16) remain off dialysis. Of the 8 HSCT-TMA patients, 5 were treated and 3 were evaluated for complement blockade. Of those treated, 80% demonstrated a hematologic response, 100% had initial renal remission; however, of all treated patients eventually returned to needing dialysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations and conclusions<\/jats:title>\n                    <jats:p>This observational study highlights the importance of the TMA multidisciplinary team to improve diagnosis and optimize outcomes of this rare condition. Future research is needed to subdivide response to various TMA to current and emerging therapies in the context of multidisciplinary care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-025-04446-z","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:41:48Z","timestamp":1758883308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Thrombotic microangiopathy multidisciplinary assessment team: demographics, final diagnosis, treatment, and outcomes"],"prefix":"10.1186","volume":"26","author":[{"given":"Matthew","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"Dileep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawaz","family":"Al Ammary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh-Ha","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpesh","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Vadpey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Abdelmalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Ahdoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoney","family":"Ferrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uttam","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekamol","family":"Tantisattamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Ling","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulian","family":"Khagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Pakbaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy M.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"4446_CR1","doi-asserted-by":"publisher","unstructured":"Tran MH, Patel S, Deasi S, Ciurea S, Lee BJ, Hanna RM. Thrombotic microangiopathy-the importance of a multidisciplinary approach. Curr Opin Nephrol Hypertens. 2023;10.https:\/\/doi.org\/10.1097\/MNH.0000000000000954 .","DOI":"10.1097\/MNH.0000000000000954"},{"issue":"6","key":"4446_CR2","doi-asserted-by":"publisher","first-page":"151345","DOI":"10.1016\/j.semnephrol.2023.151345","volume":"42","author":"P Gudsoorkar","year":"2022","unstructured":"Gudsoorkar P, Abudayyeh A, Tchakarov A, Hanna R. Onconephrology and thrombotic microangiopathy: looking beyond the horizon. Semin Nephrol. 2022;42(6):151345. https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151345.","journal-title":"Semin Nephrol"},{"issue":"2","key":"4446_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1053\/j.ackd.2021.11.006","volume":"29","author":"RM Hanna","year":"2022","unstructured":"Hanna RM, Henriksen K, Kalantar-Zadeh K, Ferrey A, Burwick R, Jhaveri KD. Thrombotic microangiopathy syndromes-common ground and distinct frontiers. Adv Chronic Kidney Dis. 2022;29(2):149\u201360 e1. https:\/\/doi.org\/10.1053\/j.ackd.2021.11.006.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"3","key":"4446_CR4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/MNH.0000000000000499","volume":"28","author":"RM Hanna","year":"2019","unstructured":"Hanna RM, Barsoum M, Vandross A, Kurtz I, Burwick R. Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition. Curr Opin Nephrol Hypertens. 2019;28(3):278\u201387. https:\/\/doi.org\/10.1097\/MNH.0000000000000499.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"4446_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.ajkd.2017.05.017","volume":"70","author":"CE Gordon","year":"2017","unstructured":"Gordon CE, Chitalia VC, Sloan JM, et al. Thrombotic microangiopathy: a multidisciplinary team approach. Am J Kidney Dis. 2017;70(5):715\u201321. https:\/\/doi.org\/10.1053\/j.ajkd.2017.05.017.","journal-title":"Am J Kidney Dis"},{"key":"4446_CR6","unstructured":"Boston University Thrombotic Microangiopathy Collaborative. Accessed 10\/13\/2023, https:\/\/www.bu.edu\/ctsi\/support-for-research\/bumc-thrombotic-microangiopathy-collaborative-butmac\/butmac\/."},{"key":"4446_CR7","doi-asserted-by":"publisher","first-page":"2050313X2094051","DOI":"10.1177\/2050313X20940510","volume":"8","author":"R Hanna","year":"2020","unstructured":"Hanna R, Zuckerman JE, Ferrey A, et al. Finding of pathological thrombomodulin gene variant in a patient with idiopathic nodular glomerulosclerosis and chronic thrombotic microangiopathy-like changes. Sage Open Med Case Rep. 2020;8:2050313X20940510. https:\/\/doi.org\/10.1177\/2050313X20940510.","journal-title":"Sage Open Med Case Rep"},{"issue":"1","key":"4446_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000512227","volume":"11","author":"EA Torres","year":"2021","unstructured":"Torres EA, Chang Y, Desai S, et al. Complement-mediated thrombotic microangiopathy associated with lupus nephritis treated with eculizumab: a case report. Case Rep Nephrol Dial. 2021;11(1):95\u2013102. https:\/\/doi.org\/10.1159\/000512227.","journal-title":"Case Rep Nephrol Dial"},{"issue":"4","key":"4446_CR9","doi-asserted-by":"publisher","first-page":"103706","DOI":"10.1016\/j.transci.2023.103706","volume":"62","author":"MH Tran","year":"2023","unstructured":"Tran MH. Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah\u2019s witness patients: a review of reported cases. Transfus Apher Sci. 2023;62(4):103706. https:\/\/doi.org\/10.1016\/j.transci.2023.103706.","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"4446_CR10","doi-asserted-by":"publisher","first-page":"103656","DOI":"10.1016\/j.transci.2023.103656","volume":"62","author":"MH Tran","year":"2023","unstructured":"Tran MH, Lee LX, Cao Y, Vu L, Pakbaz Z. Caplacizumab as rescue therapy in refractory TTP involving neurologic features. Transfus Apher Sci. 2023;62(3):103656. https:\/\/doi.org\/10.1016\/j.transci.2023.103656.","journal-title":"Transfus Apher Sci"},{"key":"4446_CR11","doi-asserted-by":"publisher","unstructured":"Tran MH, Penalosa P, Hamiduzzman A, Hanna RM. Pregnancy associated atypical hemolytic uremic syndrome triggered by massive uterine bleeding after outpatient dilatation and evacuation. J Educ Chang onconephrology (JON). 2021;6(1\u20132). https:\/\/doi.org\/10.1177\/23993693211058192.","DOI":"10.1177\/23993693211058192"},{"issue":"1","key":"4446_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.transci.2018.01.003","volume":"57","author":"PN Tran","year":"2018","unstructured":"Tran PN, Tran MH. Cobalamin deficiency presenting with thrombotic microangiopathy (TMA) features: a systematic review. Transfus Apher Sci. 2018;57(1):102\u201306. https:\/\/doi.org\/10.1016\/j.transci.2018.01.003.","journal-title":"Transfus Apher Sci"},{"issue":"4","key":"4446_CR13","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","volume":"4","author":"PK Bendapudi","year":"2017","unstructured":"Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):e157\u201364. https:\/\/doi.org\/10.1016\/S2352-3026(17)30026-1.","journal-title":"Lancet Haematol"},{"issue":"4","key":"4446_CR14","doi-asserted-by":"publisher","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","volume":"5","author":"P Coppo","year":"2010","unstructured":"Coppo P, Schwarzinger M, Buffet M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One. 2010;23;5(4):e10208. https:\/\/doi.org\/10.1371\/journal.pone.0010208.","journal-title":"PLoS One"},{"key":"4446_CR15","unstructured":"ACIP. ACIP vaccination recommendations (complement blockade). 2023 Dec 20. https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/index.html."},{"issue":"4","key":"4446_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","volume":"29","author":"E Benamu","year":"2016","unstructured":"Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016;29(4):319\u201329. https:\/\/doi.org\/10.1097\/QCO.0000000000000279.","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"4446_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-022-00567-1","volume":"37","author":"E Vonbrunn","year":"2023","unstructured":"Vonbrunn E, Buttner-Herold M, Amann K, Daniel C. Complement inhibition in kidney transplantation: where are we Now? BioDrugs. 2023;37(1):5\u201319. https:\/\/doi.org\/10.1007\/s40259-022-00567-1.","journal-title":"BioDrugs"},{"issue":"4","key":"4446_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","volume":"124","author":"S Jodele","year":"2014","unstructured":"Jodele S, Davies SM, Lane A, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;24;124(4):645\u201353. https:\/\/doi.org\/10.1182\/blood-2014-03-564997.","journal-title":"Blood"},{"issue":"3","key":"4446_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/cpt.2966","volume":"114","author":"S Jodele","year":"2023","unstructured":"Jodele S, Mizuno K, Sabulski A, Vinks AA. Adopting model-informed precision-dosing for eculizumab in transplant associated-thrombotic microangiopathy to gene therapies. Clin Pharmacol Ther. 2023;114(3):511\u201314. https:\/\/doi.org\/10.1002\/cpt.2966.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"4446_CR20","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1002\/ajh.26872","volume":"98","author":"S Jodele","year":"2023","unstructured":"Jodele S, Sabulski A. Reeling in complement in transplant-associated thrombotic microangiopathy: you\u2019re going to need a bigger boat. Am J Hematol. 2023;98(Suppl, 4):S57\u201373. https:\/\/doi.org\/10.1002\/ajh.26872.","journal-title":"Am J Hematol"},{"key":"4446_CR21","unstructured":"FDA package insert for eculizumab. 2007. https:\/\/alexion.com\/Documents\/Soliris_USPI.pdf."},{"key":"4446_CR22","unstructured":"FDA Package Insert for Ravilizumab. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761108s023lbl.pdf."},{"issue":"3","key":"4446_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","volume":"29","author":"ML Schoettler","year":"2023","unstructured":"Schoettler ML, Carreras E, Cho B, et al. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European society for Blood and marrow transplantation, American society for transplantation and cellular therapy, asia-pacific Blood and marrow transplantation group and Center for International Blood and marrow transplant research. Transplant Cell Ther. 2023;29(3):151\u201363. https:\/\/doi.org\/10.1016\/j.jtct.2022.11.015.","journal-title":"Transplant Cell Ther"},{"key":"4446_CR24","unstructured":"Cincinatti Children\u2019s TMA team website. Accessed 10\/13\/2023. https:\/\/www.cincinnatichildrens.org\/service\/t\/thrombotic-microangiopathy\/team"},{"key":"4446_CR25","unstructured":"Hopkin\u2019s TMA website. Accessed 10\/13\/2023. https:\/\/www.hopkinsmedicine.org\/nephrology\/tm-sperati."},{"key":"4446_CR26","unstructured":"Monash TMA registry. Accessed 10\/23\/2023. https:\/\/www.monash.edu\/medicine\/sphpm\/registries\/ttp-tma."},{"key":"4446_CR27","unstructured":"US TMA consortium. Accessed 10\/13\/2023. https:\/\/www.ustma.org\/about-the-consortium."},{"key":"4446_CR28","unstructured":"US TMA fast 4 TMA. Accessed 10\/13\/2023. https:\/\/www.ustma.org\/fast4tma"},{"issue":"4","key":"4446_CR29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","volume":"64","author":"G Ardissino","year":"2014","unstructured":"Ardissino G, Testa S, Possenti I, et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014;64(4):633\u201337. https:\/\/doi.org\/10.1053\/j.ajkd.2014.01.434.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"4446_CR30","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ndt\/gfw453","volume":"32","author":"T Cavero","year":"2017","unstructured":"Cavero T, Rabasco C, Lopez A, et al. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial transplant. 2017;1;32(3):466\u201374. https:\/\/doi.org\/10.1093\/ndt\/gfw453.","journal-title":"Nephrol Dial transplant"},{"issue":"3","key":"4446_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/ckj\/sfw115","volume":"10","author":"M Macia","year":"2017","unstructured":"Macia M, de Alvaro Moreno F, Dutt T, et al. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J. 2017;10(3):310\u201319. https:\/\/doi.org\/10.1093\/ckj\/sfw115.","journal-title":"Clin Kidney J"},{"issue":"2","key":"4446_CR32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000492033","volume":"48","author":"SR Olson","year":"2018","unstructured":"Olson SR, Lu E, Sulpizio E, Shatzel JJ, Rueda JF, DeLoughery TG. When to stop eculizumab in complement-mediated thrombotic microangiopathies. Am J Nephrol. 2018;48(2):96\u2013107. https:\/\/doi.org\/10.1159\/000492033.","journal-title":"Am J Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04446-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04446-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04446-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:46:15Z","timestamp":1781613975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04446-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4446"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04446-z","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Institutional Review Board (IRB) [UCI IRB protocol #2975] covering data from 01\/2020\u201307\/2024, the requirement for individual participant consent was waived in accordance with this IRB approval. This study was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Sponsorship"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"537"}}